Boosting the Body's Blood Pressure-Lowering Peptides with NEP Inhibitors

NEP inhibitor SQ 28603 enhanced both ANP effects in monkeys and BNP effects in hypertensive rats, validating the strategy behind modern heart failure drugs.

Seymour, A A et al.·Clinical and experimental pharmacology & physiology·1995·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00341Animal StudyModerate Evidence1995RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

SQ 28603 potentiated both ANP effects in monkeys (increased plasma ANP, sodium excretion) and BNP effects in hypertensive rats (blood pressure lowering, renal responses).

Key Numbers

How They Did This

Conscious monkeys received ANP infusion with or without SQ 28603. Conscious spontaneously hypertensive rats received BNP with or without NEP inhibitor. Measured plasma ANP, cGMP, sodium excretion, and blood pressure.

Why This Research Matters

NEP inhibitors protect the body's own blood pressure-lowering peptides from breakdown. This strategy became the basis for sacubitril/valsartan (Entresto), now a leading heart failure treatment.

The Bigger Picture

This research validated a concept that became one of the most important cardiovascular drug strategies in decades. By protecting natriuretic peptides from breakdown, NEP inhibitors led to sacubitril/valsartan (Entresto), which significantly reduces heart failure deaths.

What This Study Doesn't Tell Us

Animal studies in monkeys and rats. Exogenous peptide infusion does not perfectly replicate endogenous natriuretic peptide physiology.

Questions This Raises

  • ?Can NEP inhibition alone provide sufficient blood pressure and heart failure benefit, or is combination therapy always needed?
  • ?What other beneficial peptides are protected by NEP inhibition beyond ANP and BNP?

Trust & Context

Key Stat:
ANP + BNP potentiated NEP inhibition enhanced both natriuretic peptides, the strategy behind the heart failure drug Entresto
Evidence Grade:
Moderate — controlled animal studies in two species (monkeys and rats) with relevant disease model (spontaneous hypertension).
Study Age:
Published in 1995. This research helped establish the rationale for neprilysin inhibitors. Sacubitril (an NEP inhibitor) combined with valsartan became Entresto, FDA-approved in 2015 for heart failure.
Original Title:
Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Published In:
Clinical and experimental pharmacology & physiology, 22(1), 63-9 (1995)
Database ID:
RPEP-00341

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What are natriuretic peptides?

ANP and BNP are hormones released by the heart that lower blood pressure, reduce fluid retention, and protect the heart. They are the body's natural defense against heart failure.

How does this relate to Entresto?

Entresto contains sacubitril, a neprilysin inhibitor that works exactly like SQ 28603 in this study — by protecting ANP and BNP from breakdown. Combined with valsartan, it significantly reduces heart failure deaths.

Read More on RethinkPeptides

Cite This Study

RPEP-00341·https://rethinkpeptides.com/research/RPEP-00341

APA

Seymour, A A; Abboa-Offei, B E; Smith, P L; Mathers, P D; Asaad, M M; Rogers, W L. (1995). Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.. Clinical and experimental pharmacology & physiology, 22(1), 63-9.

MLA

Seymour, A A, et al. "Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.." Clinical and experimental pharmacology & physiology, 1995.

RethinkPeptides

RethinkPeptides Research Database. "Potentiation of natriuretic peptides by neutral endopeptidas..." RPEP-00341. Retrieved from https://rethinkpeptides.com/research/seymour-1995-potentiation-of-natriuretic-peptides

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.